Treatment with low-dose resveratrol reverses cardiac impairment in obese prone but not in obese resistant rats

Journal of Nutritional Biochemistry

Volumn 23, Issue 9, 2012, Pages 1163-1169

  Louis, Xavier L ^a,b   Thandapilly, Sijo J ^a,b   MohanKumar, Suresh K ^a,b   Yu, Liping ^a   Taylor, Carla G ^b   Zahradka, Peter ^a,b   Netticadan, Thomas ^a,b,c  

^a St Boniface Hospital Research Centre   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c HEART AND STROKE FOUNDATION OF CANADA   (Canada)

Author keywords

Cardiac function; Diet induced obesity; High fat diet; Obese prone; Obese resistant; Resveratrol

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; RESVERATROL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEART FUNCTION TEST; HYPERTENSION; INSULIN BLOOD LEVEL; INSULINEMIA; LIPID DIET; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; M MODE ECHOCARDIOGRAPHY; MALE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIET, HIGH-FAT; DISEASE RESISTANCE; DISEASE SUSCEPTIBILITY; ECHOCARDIOGRAPHY; HEART; HEART DISEASES; HYPERGLYCEMIA; HYPERINSULINISM; MALE; OBESITY; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STILBENES;

ANIMALIA; RATTUS;

EID: 84865063290     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.06.010     Document Type: Article

References (48)

1. Obesity and overweight. March 2011 ed: World Health Organization.
2. Andreasen C.H., Andersen G. Gene-environment interactions and obesity - further aspects of genomewide association studies. Nutrition 2009, 25:998-1003.
3. Guh D.P., Zhang W., Bansback N., Amarsi Z., Birmingham C.L., Anis A.H. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009, 9:88.
4. Pi-Sunyer X. The medical risks of obesity. Postgrad Med 2009, 121:21-33.
5. Mittendorfer B., Peterson L.R. Cardiovascular consequences of obesity and targets for treatment. Drug Discov Today Ther Strateg 2008, 5:53-61.
6. Wende A.R., Abel E.D. Lipotoxicity in the heart. Biochim Biophys Acta 2010, 1801:311-319.
7. Coppack S.W. Adipose tissue changes in obesity. Biochem Soc Trans 2005, 33:1049-1052.
8. DeClercq V., Taylor C., Zahradka P. Adipose tissue: the link between obesity and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets 2008, 8:228-237.
9. Lavie C.J., Milani R.V., Ventura H.O. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009, 53:1925-1932.
10. Grassi G., Seravalle G., Quarti-Trevano F., Scopelliti F., Dell'Oro R., Bolla G., et al. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension 2007, 49:535-541.
11. Hainer V., Toplak H., Mitrakou A. Treatment modalities of obesity: what fits whom?. Diabetes Care 2008, 31(Suppl 2):S269-S277.
12. Mauro M., Taylor V., Wharton S., Sharma A.M. Barriers to obesity treatment. Eur J Intern Med 2008, 19:173-180.
13. Riezzo G., Chiloiro M., Russo F. Functional foods: salient features and clinical applications. Curr Drug Targets Immune Endocr Metabol Disord 2005, 5:331-337.
14. Hermann D.D. Naturoceutical agents in the management of cardiovascular disease. Am J Cardiovasc Drugs 2002, 2:173-196.
15. Guerrero R.F., Garcia-Parrilla M.C., Puertas B., Cantos-Villar E. Wine, resveratrol and health: a review. Nat Prod Commun 2009, 4:635-658.
16. Juric D., Wojciechowski P., Das D.K., Netticadan T. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am J Physiol Heart Circ Physiol 2007, 292:H2138-H2143.
17. Thandapilly S.J., Wojciechowski P., Behbahani J., Louis X.L., Yu L., Juric D., et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens 2010, 23:192-196.
18. Wojciechowski P., Juric D., Louis X.L., Thandapilly S.J., Yu L., Taylor C., et al. Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats. J Nutr 2010, 140:962-968.
19. Rivera L., Moron R., Zarzuelo A., Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009, 77:1053-1063.
20. Aubin M.C., Lajoie C., Clement R., Gosselin H., Calderone A., Perrault L.P. Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther 2008, 325:961-968.
21. Levin B.E., Hogan S., Sullivan A.C. Initiation and perpetuation of obesity and obesity resistance in rats. Am J Physiol 1989, 256:R766-R771.
22. Lauterio T.J., Barkan A., DeAngelo M., DeMott-Friberg R., Ramirez R. Plasma growth hormone secretion is impaired in obesity-prone rats before onset of diet-induced obesity. Am J Physiol 1998, 275:E6-E11.
23. Levin B.E., Dunn-Meynell A.A., Banks W.A. Obesity-prone rats have normal blood-brain barrier transport but defective central leptin signaling before obesity onset. Am J Physiol Regul Integr Comp Physiol 2004, 286:R143-R150.
24. Ji H., Friedman M.I. Fasting plasma triglyceride levels and fat oxidation predict dietary obesity in rats. Physiol Behav 2003, 78:767-772.
25. Dobrian A.D., Davies M.J., Prewitt R.L., Lauterio T.J. Development of hypertension in a rat model of diet-induced obesity. Hypertension 2000, 35:1009-1015.
26. Dobrian A.D., Davies M.J., Schriver S.D., Lauterio T.J., Prewitt R.L. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension 2001, 37:554-560.
27. Sefcikova Z., Hajek T., Lenhardt L., Racek L., Mozes S. Different functional responsibility of the small intestine to high-fat/high-energy diet determined the expression of obesity-prone and obesity-resistant phenotypes in rats. Physiol Res 2008, 57:467-474.
28. Lauterio T.J., Davies M.J., DeAngelo M., Peyser M., Lee J. Neuropeptide Y expression and endogenous leptin concentrations in a dietary model of obesity. Obes Res 1999, 7:498-505.
29. Fam B.C., Morris M.J., Hansen M.J., Kebede M., Andrikopoulos S., Proietto J., et al. Modulation of central leptin sensitivity and energy balance in a rat model of diet-induced obesity. Diabetes Obes Metab 2007, 9:840-852.
30. Hassanain M., Levin B.E. Dysregulation of hypothalamic serotonin turnover in diet-induced obese rats. Brain Res 2002, 929:175-180.
31. Olfert E.D., Cross C.M., McWilliam A.A. Guide to the care and use of experimental animals 1993, vol. 1. Canadian Council on Animal Care, Ottawa, Canada. 2nd ed.
32. Cipolla M.J., Smith J., Bishop N., Bullinger L.V., Godfrey J.A. Pregnancy reverses hypertensive remodeling of cerebral arteries. Hypertension 2008, 51:1052-1057.
33. Cantor E.J., Babick A.P., Vasanji Z., Dhalla N.S., Netticadan T. A comparative serial echocardiographic analysis of cardiac structure and function in rats subjected to pressure or volume overload. J Mol Cell Cardiol 2005, 38:777-786.
34. Gradman A.H., Wilson J.T. Hypertension and diastolic heart failure. Curr Cardiol Rep 2009, 11:422-429.
35. Morse S.A., Gulati R., Reisin E. The obesity paradox and cardiovascular disease. Curr Hypertens Rep 2010, 12:120-126.
36. Sulaiman M., Matta M.J., Sunderesan N.R., Gupta M.P., Periasamy M., Gupta M. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2010, 298:H833-H843.
37. Joo J.I., Yun J.W. Gene expression profiling of adipose tissues in obesity susceptible and resistant rats under a high fat diet. Cell Physiol Biochem 2011, 27:327-340.
38. Mathieu P., Lemieux I., Despres J.P. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther 2011, 87:407-416.
39. McFarlane S.I., Banerji M., Sowers J.R. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713-718.
40. Deng J.Y., Hsieh P.S., Huang J.P., Lu L.S., Hung L.M. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways. Diabetes 2008, 57:1814-1823.
41. Bogaert Y.E., Linas S. The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2009, 5:101-111.
42. Macarulla M.T., Alberdi G., Gomez S., Tueros I., Bald C., Rodriguez V.M., et al. Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet. J Physiol Biochem 2009, 65:369-376.
43. Gurusamy N., Das D.K. Autophagy, redox signaling, and ventricular remodeling. Antioxid Redox Signal 2009, 11:1975-1988.
44. Berg A.H., Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96:939-949.
45. Serpillon S., Floyd B.C., Gupte R.S., George S., Kozicky M., Neito V., et al. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol 2009, 297:H153-H162.
46. Olholm J., Paulsen S.K., Cullberg K.B., Richelsen B., Pedersen S.B. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int J Obes (Lond) 2010, 34:1546-1553.
47. Zhang H., Morgan B., Potter B.J., Ma L., Dellsperger K.C., Ungvari Z., et al. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am J Physiol Heart Circ Physiol 2010, 299:H985-H994.
48. Chan A.Y., Dolinsky V.W., Soltys C.L., Viollet B., Baksh S., Light P.E., et al. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem 2008, 283:24194-24201.